New York State Common Retirement Fund Buys 90,145 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

New York State Common Retirement Fund raised its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 190.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 137,440 shares of the company's stock after purchasing an additional 90,145 shares during the quarter. New York State Common Retirement Fund owned 0.11% of Vaxcyte worth $5,190,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Xponance Inc. raised its position in Vaxcyte by 4.7% in the first quarter. Xponance Inc. now owns 9,320 shares of the company's stock valued at $352,000 after purchasing an additional 415 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Vaxcyte by 10.9% during the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock worth $112,000 after acquiring an additional 293 shares during the last quarter. Brown Advisory Inc. raised its position in shares of Vaxcyte by 2.5% during the first quarter. Brown Advisory Inc. now owns 570,258 shares of the company's stock worth $21,533,000 after acquiring an additional 14,049 shares during the last quarter. Envestnet Asset Management Inc. raised its position in shares of Vaxcyte by 75.4% during the first quarter. Envestnet Asset Management Inc. now owns 96,600 shares of the company's stock worth $3,648,000 after acquiring an additional 41,517 shares during the last quarter. Finally, GF Fund Management CO. LTD. raised its position in shares of Vaxcyte by 22.0% during the first quarter. GF Fund Management CO. LTD. now owns 3,192 shares of the company's stock worth $121,000 after acquiring an additional 575 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PCVX. Cantor Fitzgerald began coverage on Vaxcyte in a research report on Tuesday, April 22nd. They set an "overweight" rating for the company. The Goldman Sachs Group lowered their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Finally, Bank of America lowered their target price on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Vaxcyte currently has an average rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Trading Up 1.1%

Shares of NASDAQ:PCVX traded up $0.39 during mid-day trading on Friday, hitting $36.63. 1,088,735 shares of the company traded hands, compared to its average volume of 1,427,526. The stock has a market cap of $4.73 billion, a P/E ratio of -9.18 and a beta of 1.19. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06. The stock has a 50-day moving average price of $34.38 and a two-hundred day moving average price of $52.17.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the prior year, the firm earned ($0.85) earnings per share. As a group, analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.